Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Peer-reviewed Zyesami, great!!!
https://www.sciencedirect.com/science/article/pii/S1053249821020702
The global pneumonia therapeutics market size was estimated at USD 11.9 billion in 2016 and is anticipated to grow at a CAGR of 8.0% throughout the forecast period. Increasing incidence of pneumococcal disease is a high impact rendering driver. Over the years, there has been a significant upsurge in number of community-acquired and ventilator-associated bacterial pneumonia. According to World Health Organization, the annual incidence is approximately 150.7 million cases, of which 7% to 13% require intensive treatment.
https://www.grandviewresearch.com/industry-analysis/pneumonia-market
Ratna1, my siblings and I are busy with parents, in particular our mother. She called having difficulty breathing, having to use several pillows be able to breath better while trying to sleep. We took her to a clinic, did a battery of tests and found fluid in her lungs. COVID-19 negative. High blood pressure. Heart murmur. She was given Furosemide. Took her to nephrologist, said could be aortic valve stenosis. Prescribed Furosemide and potassium pills. Setup cardiologist appointment, he recommended and did nuclear test. We are now waiting for next appointment on Tuesday to discuss results of nuclear test. In the meantime she had started taking vitamin K2 + D3 and she is doing better.
https://homedialysis.org/news-and-research/blog/98-vitamin-k2-a-little-known-nutrient-with-big-potential-benefits-for-ckd
I read the excellent posts of several people on this board, defending their RLFTF property/value from unethical opportunists. Great job!!!
What say you doctor??? Feeling better in minutes???
Well, we are back on that horse again. I read...For pulmonary sarcoidosis, the initiation dosage is 20 to 40 mg per day of prednisone or its equivalent for one to three months. Every-otherday dosing also may be considered. In patients who respond, the prednisone dose should be tapered to 5 to 10 mg per day or every other day for a minimum of 12 months.
https://www.aafp.org/afp/2004/0715/p312.html
CRIPPLING...
Sarcoidosis is a systemic granulomatous disease of unknown cause affecting young and middle-aged adults. Patients commonly present with bilateral hilar lymphadenopathy, pulmonary infiltrates, and ocular and skin lesions. The heart, liver, spleen, salivary glands, muscles, bones, kidneys, and central nervous system also may be involved.
https://www.aafp.org/afp/2004/0715/p312.html
AND VIP??? Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis =================
Rationale: Previous studies suggest an important immunoregulatory role of vasoactive intestinal peptide (VIP) in experimental models of chronic noninfectious inflammation. Sarcoidosis is characterized by noncaseating epitheloid cell granulomas, where excessive tumor necrosis factor-a production by pulmonary macrophages plays a critical role in granuloma formation and disease progression, which may lead to fatal organ dysfunction.
———— Objectives: To test whether inhaled VIP has an immunoregulatory role. Sarcoid alveolitis was used as a prototype of immune-mediated chronic lung inflammation. —————————-
Conclusions: This study is the first to show the immunoregulatory effect of VIP in humans, and supports the notion of inhaled VIP as an attractive future therapy to dampen exaggerated immune responses in lung disorders. Thus, the inhalation of neuropeptides may be developed into a new therapeutic principle for chronic inflammatory lung disorders in humans.
https://www.atsjournals.org/doi/full/10.1164/rccm.200909-1451OC
The global sarcoidosis therapeutics market is expected to be driven by research undertaking and funding to control the rising prevalence of sarcoidosis. For instance, the National Institutes of Health (NIH) granted US$ 8.3 Mn to the University of Pittsburgh to explore the relationship between gene activation process, sarcoidosis disease progression, and lung bacteria. Other major trends in global sarcoidosis therapeutics include strategic alliances. Pharma companies are working together or with research organizations to develop medications for the treatment of sarcoidosis. In March 2015, THERAMetrics Holding AG signed collaboration and licensing agreement with Centurion Pharma to develop and commercialize Aviptadil for sarcoidosis. In December 2018, aTyr Pharma announced collaboration with Foundation for Sarcoidosis Research (FSR) for assistance in clinical trial site initiation and patient enrollment for pulmonary sarcoidosis. Institutions and organizations are spreading awareness about sarcoidosis among people. In the U.K., the British Lung Foundation (BLF) is creating awareness about the early diagnosis and therapeutics of sarcoidosis.
https://www.transparencymarketresearch.com/sarcoidosis-therapeutics-market.html
LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global sarcoidosis therapeutics market to have an incremental growth of $46 million during the forecast period [Global Sarcoidosis Therapeutics Market 2019-2023], according to their latest market research report. The growth momentum of the market is expected to accelerate in the year-over-year growth.
https://www.businesswire.com/news/home/20190104005221/en/Global-Sarcoidosis-Therapeutics-Market-2019-2023-Rising-Awareness-about-Sarcoidosis-to-Boost-Demand-Technavio
Correction: pulmonary sarcoidosis
Pulmonary fibrosis, going after low hanging fruit while we wait???
https://www.clinicaltrialsregister.eu/ctr-search/search?query=Aviptadil+
FALSE Alert: NO DIFFERENCE BETWEEN YOUR VERSION ANT THE OLDER ONE: ALL THE SAME, AND NOTHING HAS CHANGED
I received this morning, at 6:00 European time, an alert that the 23-Feb-2021 Press Release on the NeuroRX site had been updated.
Here is the new title of that Press Release :
-------------------------------------
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
-------------------------------------
and here below is the updated part of the 23-Feb-2021 Press Release - very different POSITIVE language which shows a massive 46% improvement at Day 28 :
==========================
At 28 days, patients treated with ZYESAMI™ demonstrate 35% higher likelihood of recovery from respiratory failure with continued survival compared to patients treated with placebo (Hazard Ratio 1.53; P=.08). In tertiary care hospitals, ZYESAMI-treated patients were 46% more likely to recover and return home before day 28 (Hazard Ratio controlling for age and severity 1.84; P=.058). Should these trends continue through day 60, they have the potential to reach statistical significance. At day 28, a highly significant 10-day difference in median time to recovery and hospital discharge has emerged in ZYESAMI-treated patients compared to those treated with placebo (P<.006).
==========================
Ilka ~ from Y@h00 Rlftf conversations
https://www.neurorxpharma.com/latest-news/
JUST A REMINDER:
Along with other treatments, ZYESAMI will bring normality back to the whole world as a main player during the next 18-24 months. It will be in every household in the western and Eastern world but also in the emerging countries. These emerging countries will be very important because Zyesami will be affordable even for the poorest countries. But it will also be a new Big Drug for all kind of lung issues. The patent is good for several more years from this year on. And of course This will be at a few dollars only days after first approval. And weeks after we will be listed on the main exchanges. It's as easy as that. No need for RS and two digits latest when the inhaler is on the market. And have a look in 24 month. My guess? Three digits.
After markets crashes that may come, stocks like us will be a save harbor for a huge number of investors.
So I think we are fine.
GLTA ~ HANS from Y@h00 RLFTF conversations
Research into VIP’s mechanisms of action is a relic of an older era in biology, when researchers focused on cellular pathways and genomics was not yet a word. Although VIP was once viewed as a promising drug and substantial resources were invested in elucidating its pharmacokinetics, toxicology, and safety pharmacology, pharmaceutical companies found it challenging to administer, given the need for inhaled or IV administration and challenging to formulate. Pulmonary drugs are notoriously difficult to develop, given regulatory requirements for long-term inhaled toxicology studies in multiple species, including primates (Tepper 2016). FDA has asserted that these preclinical toxicology requirements must be observed in the case of candidate drugs to treat COVID-19. VIP, on the other hand, completed four-species toxicology and safety pharmacology studies in both intravenous and inhaled dosage forms but did not proceed to the market for lack of a compelling clinical target. Phase 2 trials in sarcoidosis (Prasse 2010), pulmonary hypertension (Leuchte 2008), pulmonary fibrosis, and allergy/asthma suggest that VIP has no major toxicities when inhaled at doses of 300µg/day and that the toxic dose is at least 25x higher.
https://www.authorea.com/users/321659/articles/450881-perspective-the-potential-role-of-vasoactive-intestinal-peptide-in-treating-covid-19
I hear (read) you!!!
SEEMS THEY ARE READY FOR EUA, YES???
“Although our current production methods yield a drug that is sufficiently stable for emergency use...”
https://www.businesswire.com/news/home/20210309005660/en/NeuroRX-and-TFF-Pharmaceuticals-Announce-Entering-Into-Feasibility-Collaboration
ARE THEY GETTING READY FOR ASTHMA NEXT???
...a long-term, shelf-stable formulation will be needed for ongoing use of ZYESAMI
IF ANY ENTITY WANTS THE PHARMACEUTICAL WORLD MARKET, THE USA MARKET IS STILL PART OF IT ———————
The United States was the largest pharmaceutical market in 2019, generating roughly 45 percent of total revenues worldwide. China established itself as the second-largest market with a sales share of 8.5 percent.
https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-pharmaceutical-markets/
WHY IS DR JAVITT LOOKING BEYOND COVID-19??? (...a long-term, shelf-stable formulation will be needed for ongoing use of ZYESAMI) THAT’S THE JOB OF RELIEF UNLESS THEY BOTH CONCUR ON THE WAY FORWARD...??? ————————
“We are excited that ZYESAMI has demonstrated a highly significant reduction in time to hospital discharge for seriously ill COVID-19 patients treated with High Flow Nasal Oxygen, along with an increased likelihood of recovery and excellent safety,” said Jonathan C. Javitt, M.D., M.P.H., CEO of NeuroRx. “Although our current production methods yield a drug that is sufficiently stable for emergency use, a long-term, shelf-stable formulation will be needed for ongoing use of ZYESAMI, once the pandemic subsides. The thin-film freezing technology holds great promise in potentially making this available to patients with other stages of COVID-19 with an inhaled form of ZYESAMI.”
https://www.businesswire.com/news/home/20210309005660/en/NeuroRX-and-TFF-Pharmaceuticals-Announce-Entering-Into-Feasibility-Collaboration
RELIEF NEEDS A SMOOTH OPERATOR/CREW TO NAVIGATE THE CHOPPY FDA SEAS
Early in the Covid-19 pandemic, a research and development (R&D) consultant at Swiss pharma company Relief Therapeutics, Yves Sagot, realised that a drug developed in the early 2000s for acute respiratory distress and other lung diseases and acquired by Biogen could be effective at treating Covid-19.
Relief then reached out to US-based NeuroRx to help them co-develop this drug for Covid-19, because the latter has a “history of taking already known molecules and moving them very quickly through the FDA”, explains NeuroRx CEO and chairman Professor Jonathan Javitt.
The drug in question is now called RLF-100 and is a patented formulation of aviptadil, which is a synthetic human vasoactive intestinal polypeptide (VIP). This short peptide “protects the lung from all sorts of injuries”, explains Javitt. “We now know that this peptide is extremely effective in protecting the cell that is attacked by the SARS-CoV-2 virus that causes Covid-19.”
https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/
ANY CHANCE OF A MERGER, BEYOND COVID-19 EUA???
That’s why you are here for, you know it all!!!
IF ZYESAMI (TM) becomes a COVID-19 home-run, how soon before RLFTF gets bought???
The SPAC merger process with a target company may be completed in as little as three to four months, which is substantially shorter than a typical traditional IPO timeline. Accordingly, a target company must accelerate public company readiness well in advance of any SPAC merger.
https://www.pwc.com/us/en/services/audit-assurance/accounting-advisory/spac-merger.html
WHAT IF ZYESAMI (TM) TURNS OUT TO BE A COVID-19 HOME RUN??? ———— What studies follow and how fast??? Drug repurposing??? —————————
Drug repurposing is one such strategy. Many agents approved for other uses already have been tested in humans, so detailed information is available on their pharmacology, formulation and potential toxicity. Because repurposing builds upon previous research and development efforts, new candidate therapies could be ready for clinical trials quickly, speeding their review by the Food and Drug Administration and, if approved, their integration into health care. ~ NIH > NCATS. https://ncats.nih.gov/preclinical/repurpose
———————-
VIP BEYOND COVID-19, if pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, can multiple inhaled VIP clinical studies be conducted at same locations, concurrently??? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090995/
——————-
DR., WHAT SAY YOU???
Any chance of a Pfizer-like split???
Pfizer (PFE) has 6 splits in our Pfizer stock split history database. The first split for PFE took place on July 01, 1983. This was a 2 for 1 split, meaning for each share of PFE owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. PFE's second split took place on April 01, 1991. This was a 2 for 1 split, meaning for each share of PFE owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split. PFE's third split took place on July 03, 1995.
https://www.stocksplithistory.com/pfizer/
Ratna1, good find/repost, credit to OU3!
Hear, hear!! Excellent analysis ratna1!! Than you!! —————————————
Quote:
As for Zyesami, this week will be crucial, as the pressure is on to see the 60 day results, but interestingly it’s not their only shot to be discovered. The iSpy inhaled study is still in the works and given that Covid is not going away anytime soon according to nearly all the knowledgeable medical advice, I like Zyesami’s chances! ~ ratna1 —————————-
I LIKE MY CHANCES WITH THE AMAZING NEUROPEPTIDE!! —————————-
Quote:
I like my chances with RLFTF and BRPAW, BRPR, BRPA family of investments. Go #RLFTF #BRPA ~ ratna1
Go_wamu, I’m with you on the relationship between the FDA and Big Pharma.
Quote: ...the FDA is in bed with BigPharma? More and more people are suffering from anxiety, depression and other such disorders, such as hopelessness and despair, and the number of people has increased dramatically due to the COVID-19 pandemic. ~go_wamu ——————
While I have your attention, Neuro RX/Relief Therapeutics RLF-100 IV is on Phase III of their modified Phase 2b/3 clinical trials. ————
Phase II >>>
In Phase II, a drug is evaluated for its efficacy and safety in patients with specific diseases. As a rule, these are placebo - controlled trials. Sometimes, Phase II of a clinical trial is divided into phases IIa and IIb. The purposes of Phase II trial are to evaluate short-term safety of a drug (IIa) and to confirm clinical efficacy of a drug and determine the therapeutic dose range (IIb).
——————
Phase III >>>
In Phase III clinical trials, the study drug is given to large groups of patients (thousands of subjects) of different age groups, with different concomitant diseases. These trials are conducted at multiple scientific research sites in different countries. Phase III trials are often randomized controlled studies. These trials investigate all aspects of treatment including assessment of risk / benefit ratio. According to the results of Phase III clinical trials, the decision on registration of the drug product or refusal in its registration is made. Phase III of a clinical trial may be divided into phases IIIa and IIIb as well.
————-
Once Zyesami (TM) IV and inhaler get approved, what studies follow and how fast??? Drug repurposing??? —————-
Drug repurposing is one such strategy. Many agents approved for other uses already have been tested in humans, so detailed information is available on their pharmacology, formulation and potential toxicity. Because repurposing builds upon previous research and development efforts, new candidate therapies could be ready for clinical trials quickly, speeding their review by the Food and Drug Administration and, if approved, their integration into health care. ~ NIH > NCATS.
https://ncats.nih.gov/preclinical/repurpose
Once SPAC merger of Neuro RX and Black Rock is complete, do you see a merger acquisition of Relief Therapeutics by the new Nasdaq-listed Neuro RX??? Would this be supported by large investors like Ives Sagot and GEM???
https://sonix.ai/r/xtrz7PUXeMjvyvbr48n12Ucj/share
VIP, AMAZING NEUROPEPTIDE———
Role of vasoactive intestinal peptide in osteoarthritis ——————————
Vasoactive intestinal peptide (VIP) plays important roles in many biological functions, such as, stimulation of contractility in the heart, vasodilation, promoting neuroendocrine-immune communication, lowering arterial blood pressure, and anti-inflammatory and immune-modulatory activity. Osteoarthritis (OA) is a chronic and degenerative bone disease, which is one of the most common causes of disability and most common in both sexes as people become older. Interestingly VIP can prevent chronic cartilage damage and joint remodeling......A number of studies indicated that up-regulation of VIP can counteract the action of pro-inflammatory stimuli and alleviate the pain in OA. More clinical investigations are necessary to determine the biology of VIP and its therapeutic potential in OA that might represent the future standards of care for OA.
https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0280-1
The osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.
https://www.marketsandmarkets.com/Market-Reports/osteoarthritis-therapeutics-market-209565994.html
Excellent find on VIP ratna1!! ——————
Anxiety Disorders and Depression Treatment Market Size Worth USD 13.03 Billion at 2.6% CAGR; Market Leaders Such as Pfizer and Eli Lilly to Make Massive Investments to Boost R&D Capabilities: Fortune Business Insights™
https://www.globenewswire.com/news-release/2021/02/01/2167163/0/en/Anxiety-Disorders-and-Depression-Treatment-Market-Size-Worth-USD-13-03-Billion-at-2-6-CAGR-Market-Leaders-Such-as-Pfizer-and-Eli-Lilly-to-Make-Massive-Investments-to-Boost-R-D-Capa.html
Ratna1, or this one...
Immunoglobulin A (IgA) is an antibody blood protein that's part of your immune system. Your body makes IgA and other type of antibodies to help fight off sickness. Having an IgA deficiency means that you have low levels of or no IgA in your blood. https://www.hopkinsmedicine.org/health/conditions-and-diseases/immunoglobulin-a-deficiency The body makes different antibodies, or immunoglobulins, to fight different things. For example, the antibody for chickenpox isn't the same as the antibody for mononucleosis. Sometimes, the body may even mistakenly make antibodies against itself, treating healthy organs and tissues like foreign invaders. This is called an autoimmune disease. https://kidshealth.org/en/parents/test-immunoglobulins.html HOW DO VACCINES WORK??? A vaccine works by training the immune system to recognize and combat pathogens, either viruses or bacteria. To do this, certain molecules from the pathogen must be introduced into the body to trigger an immune response. These molecules are called antigens, and they are present on all viruses and bacteria. https://www.publichealth.org/public-awareness/understanding-vaccines/vaccines-work/ WHAT’S THE DIFFERENCE BETWEEN IG [Immuno Globulin] AND VACCINES? IG is a substance made up of antibodies that are naturally made by the body to provide protection from certain diseases. A vaccine is a substance made up of actual viruses or bacteria that stimulate the body to make more antibodies. https://www.verywellhealth.com/what-is-immune-globulin-1760124 The addition of VIP was associated with a significant increase in the production of IgA, whereas IgG levels were significantly reduced. Both these effects were restricted to LPMC. LDA showed that the IgA-enhancing effect was associated with an increase in the number of IgA-producing precursor cells and with variation in the regulatory phenomena involved in IgA production. https://pubmed.ncbi.nlm.nih.gov/8119526/ Vasoactive intestinal peptide (VIP), a peptide produced by immune cells, exerts a wide spectrum of immunological functions that control the homeostasis of the immune system. In the last decade, VIP has been clearly identified as a potent anti-inflammatory factor, both in innate and adaptive immunity. https://pubmed.ncbi.nlm.nih.gov/16312132/ COULD RLF TAKE A CHUNK OUT OF THE VACCINE MARKET??? The global vaccine market size accounted for $32,462 million in 2019, and is expected to reach $54,150 million by 2027, registering a CAGR of 6.6% from 2020 to 2027.
https://www.globenewswire.com/news-release/2020/12/09/2141957/0/en/Global-Vaccine-Market-to-Reach-US-57-Billion-by-2025-Fostered-by-Sudden-Outbreak-of-COVID-19-By-IMARC-Group.html
Ratna1, maybe you are referring to this...
Most people with an IgA deficiency don’t have any symptoms of the health problem. It’s usually found on a blood test, if it’s found at all. About 1 in 4 to 1 in 2people with selective IgA deficiency will be affected. Some people with an IgA deficiency are more likely to get frequent infections. These can include sinus, lung, and digestive infections. Some people with IgA deficiency also are more likely to have allergies, and digestive and autoimmune problems such as celiac disease or lupus.
https://www.hopkinsmedicine.org/health/conditions-and-diseases/immunoglobulin-a-deficiency
The addition of VIP was associated with a significant increase in the production of IgA, whereas IgG levels were significantly reduced. Both these effects were restricted to LPMC. LDA showed that the IgA-enhancing effect was associated with an increase in the number of IgA-producing precursor cells and with variation in the regulatory phenomena involved in IgA production.
https://pubmed.ncbi.nlm.nih.gov/8119526/
Ms. Pegs1,
Did you ever feel under threat by any FDA arbitrary actions that would have impeded access to your VIP compound drug???
VIP was first used in CIRS patients in November, 2008. Its use has revolutionized care of CIRS in that not only does VIP correct symptoms and proteomics seen in affected patients, but it also corrects gray matter nuclear atrophy (think of early Alzheimer’s!) and the transcriptomic (gene activation and suppression) abnormalities that are the ultimate source of this illness. Without VIP, patients will be forced to either suffer needlessly (this illness can kill people too) or search for another neuroregulatory peptide that can safely reproduce the extraordinary benefits of VIP.
https://www.survivingmold.com/save-vip/vip-faces-removal-from-fda-compounding-list
The FDA wanted a multi-million dollar IND track for the compounded drug, yes??? Finally, VIP is in a multi-million IND track!!
They said aviptadil is shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes while also preventing synthesis of cytokines in the lung. It is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has been granted FDA fast track designation, FDA emergency use IND authorisation, and an expanded access protocol.
https://www.reuters.com/article/us-health-coronavirus-relief-hldg-idINKCN2520ED
As soon as Zyesami (TM) gets approved, it is my understanding you will go for the Zyesami (TM) IV drug, yes??? If at all possible, you will follow the IV drug with the inhaled Zyesami (TM), yes??? I’m sure your lung specialist will be on top of this.
“We started off giving it [aviptadil] to the people who were critically ill with COVID-19—people who were on ventilators, high-flow oxygen. And we are now just starting studies where it will be given in an inhaled form for people who are less sick,” NeuroRx CEO and Chairman Jonathan Javitt, MD, MPH, told Contagion. “Most pulmonary drugs are best given in inhaled form but once someone has COVID distress and is on a ventilator there is a lot of debris in the lungs and reasons to give it intravenously.”
https://www.contagionlive.com/view/showing-promising-recovery-results-from-respiratory-failure-in-covid-19-patients
Hi ratna1! I’m traveling for several days and will be back home on Monday! I will post/reply to your posts ASAP. I guess is your turn to post-away!
No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions.
https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-12-45
Worldwide increase incidences of allergic diseases have heightened the interest of clinicians and researchers to understand the role of neuroendocrine cells in the recruitment and activation of inflammatory cells. Several pieces of evidence revealed the association of neuropeptides in the pathogenesis of allergic diseases. Importantly, one such peptide that is secreted by neuronal cells and immune cells exerts a wide spectrum of immunological functions as cytokine/chemokine is termed as Vasoactive Intestinal Peptide (VIP).
https://pubmed.ncbi.nlm.nih.gov/28964637/
The global allergy diagnostics and therapeutics market size was valued at USD 32.06 billion in 2018 and is anticipated to expand further at a strong CAGR of 6.3% over the forecast period.
https://www.google.com/search?q=allergic+diseases+therapeutics+market+size&ie=UTF-8&oe=UTF-8&hl=en-us&client=safari
Ms. Pegs1, thank you for your candid answers! I hope soon enough you’ll be able to have Zyesami(TM) IV first and if at all possible, the inhaled Zyesami (TM) afterwards. I agree, I believe Zyesami (TM) will be more powerful than the compounded drug. Best to you!
https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-12-45
Here is another page link with other links embedded, from Dr Ritchie Showmaker M.D., in the defense of VIP before the FDA
https://pdlabsrx.com/pages/vip-supported-documents
More on VIP from Dr. Shoemaker
Ms. Pegs1, how did you manage your lungs health condition before the Hopkinton drug/compound??? It seems the FDA wanted to arbitrarily end it, yes??? What do you expect from Zyesami(TM) in comparison to the Hopkinton drug???
VIP BEYOND COVID-19, if pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, can multiple inhaled VIP clinical studies be conducted at same locations, concurrently???
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090995/
DR., WHAT SAY YOU???
VIP, ARE WE THERE YET???
Recognition of the central functions VIP plays in cellular processes is focusing our attention on this “very important peptide” as an important new candidate for therapeutic intervention and drug development.
https://pdlabsrx.com/pages/vasoactive-intestinal-peptide-vip-nasal-spray-treatment
Wow!! Powerful, brother.............
Comment: At 28 days, a Aviptadil patients treated with HFNC were 35% - 46% more likely to recover, return home, and survive to 28 days compared to placebo-treated patients, with a trend level of significance. Aviptadil patients additionally demonstrated a highly statistically significant and clinically dramatic ten day reduction in hospitalization time. Should similar findings be observed at 60 days, Emergency Use Authorization will be sought.
THE AMAZING NEUROPEPTIDE, VIP
A Message from Our Friends at Hopkinton Drug about how you can make your voice heard on VIP.
https://www.survivingmold.com/save-vip/a-message-from-our-friends-at-hopkinton-drug-about-how-you-can-make-your-voice-heard-on-vip
THE VIP TRAIN IS SOUNDING LOUDER
BARTSDAD, Dr. Shoemaker said essentially a cure, but if you walk back into a mold environment the subject will have a relapse. The relapse won’t be as bad as originally, before VIP
BARTSDAD, Zye (thanks)!!
R_deckard, Zye (thanks)!!
VIP MAIN EFFECT IMMEDIATELY IS ENDORPHIN